

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

Brilliant Violet 510(TM) anti-mouse CD3

RRID:AB_2561387

Type: Antibody

Proper Citation

BioLegend Cat# 100233, RRID:AB_2561387

Antibody Information

URL: http://antibodyregistry.org/AB_2561387

Proper Citation: BioLegend Cat# 100233, RRID:AB_2561387

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2561387

Vendor: BioLegend

Catalog Number: 100233

Alternative Catalog Numbers: 100234

Record Creation Time: 20250819T235936+0000

Record Last Update: 20250820T070254+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 510(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Damara A, et al. (2026) Protocol for inducing deep vein thrombosis in C57BL/6J mice using the inferior vena cava stenosis model. STAR protocols, 7(3), 104665.

de Lima J, et al. (2026) HIF-1 α + CD4 $^{+}$ T cells coordinate a tissue-resident immune cell network in the lung. Immunity, 59(4), 1092.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. Cell reports. Medicine, 7(4), 102706.

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. Cell reports. Medicine, 6(11), 102434.

Barrington J, et al. (2025) Interleukin-1 regulates myeloid cell trafficking and cerebral blood flow following intracerebral haemorrhage. Disease models & mechanisms, 18(10).

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. Cell reports. Medicine, 6(8), 102251.

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. iScience, 28(5), 112508.

Simons B, et al. (2025) Clonal persistence dominates homeostatic intestinal IgA responses. Immunity, 58(12), 3061.

Song Q, et al. (2025) Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. Cell reports, 44(8), 116132.

Shang L, et al. (2024) Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. Cell reports. Medicine, 5(7), 101648.

Restaino AC, et al. (2024) TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION. *bioRxiv : the preprint server for biology*.

Beck JD, et al. (2024) Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. *Cancer cell*.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. *Cancer cell*, 42(7), 1286.

Du C, et al. (2024) Mitochondrial serine catabolism safeguards maintenance of the hematopoietic stem cell pool in homeostasis and injury. *Cell stem cell*, 31(10), 1484.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Bhaskar A, et al. (2023) SIRT2 inhibition by AGK2 enhances mycobacteria-specific stem cell memory responses by modulating beta-catenin and glycolysis. *iScience*, 26(5), 106644.

Zhang D, et al. (2023) PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. *Cell metabolism*, 35(3), 517.

Ma C, et al. (2022) Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. *Cancer cell*, 40(9), 986.

Xiong A, et al. (2022) Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. *EBioMedicine*, 83, 104239.

Menzel L, et al. (2021) Lymphocyte access to lymphoma is impaired by high endothelial venule regression. *Cell reports*, 37(4), 109878.